Vivtex

📍 Boston, United States🗓 Founded 2018👥 20 employees💰 Last funded 2024
Biotechnology Research🌐 vivtex.com
Website LinkedIn
Vivtex strives to transform drug development using a new platform technology called gastrointestinal tract organ robotic interface system (GI-ORIS™) that enables robotic screening with fully intact and functional organs. GI-ORIS™ technology was developed in the Langer lab at MIT and can be used for various applications (e.g. oral delivery of biologics, drug toxicity mitigation, spatial and temporal drug delivery). Vivtex leverages these unique capabilities of the GI-ORIS™ to develop new oral therapeutics. Vivtexs mission is to serve patients by increasing the efficacy, safety and adherence of existing and novel therapies. The company is in preclinical stage and has multiple drug development programs including reformulations of existing drugs as well as new chemical entities. The company was co-founded by Professor Robert Langer (MIT), Dr. Giovanni Traverso (Harvard Medical School), Doug Eby (Cambridge Science), and Thomas von Erlach.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2018
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Vivtex?
Vivtex has 1 investors on record on gritt.io and 1 late-stage investors.
When did Vivtex last raise funding?
The most recent investment in Vivtex recorded on gritt.io was in 2024.
When was Vivtex founded?
Vivtex was founded in 2018.
What industry is Vivtex in?
Vivtex operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Vivtex based?
Vivtex is headquartered in Boston, United States.